Abstract. The clinical efficacy of colorectal tumor treatment is restricted due to platinum agent resistance. Translesion DNA synthesis (TLS) has been shown to contribute to this resistance; however, the exact molecular mechanism remains unknown. The present study aimed to investigate the possible function of the core of the TLS polymerase mitotic arrest deficient 2 like 2 (MAD2L2) in drug sensitivity, in order to provide a treatment rationale for platinum‑based chemotherapy in colon cancer. In the present study, MAD2L2 was knocked down using MAD2L2‑specific small interfering (si)RNA. HCT116 and SW620 cells were treated with oxaliplatin and MG132; oxaliplatin is a platinum compound that induces DNA damage and MG132 is a potent proteasome inhibitor. Cell viability was determined using an MTT assay. Cell apoptosis was examined via flow cytometry and TUNEL assay. The activity of proteasome 26S subunit, non‑ATPase 13 (PSMD13) was detected using ELISA, while the expression levels of apoptotic‑related proteins were detected via western blotting. The results demonstrated that cells treated with oxaliplatin or MG132 alone had decreased viability, but a synergistic effect was not observed after co‑treatment. In addition, the knockdown of MAD2L2 caused by siMAD2L2 or oxaliplatin treatment increased the expression levels of the pro‑apoptotic proteins Bax and Bak and decreased the expression levels of the anti‑apoptotic protein Bcl‑2, compared with the negative control group. Moreover, MG132 alleviated the decrease in MAD2L2 expression, while reducing siMAD2L2‑induced cell apoptosis. These results indicate that oxaliplatin promotes siMAD2L2‑induced apoptosis in colon cancer cells. This process was associated with the Bcl‑2 and ubiquitin‑proteasome pathway. Overall, the present study provides a theoretical basis for improving the clinical efficacy of colon cancer by combining chemotherapy and gene therapy.

Introduction

Globally, colorectal cancer (CRC) is the third most common form of cancer, and is the second most common cause of cancer‑associated mortality (1,2). Although CRC is considered to be mainly prevalent in developed countries, the incidence is also rising rapidly in developing countries (3,4). Further basic and clinical research would undoubtedly accelerate the progress in the treatment of CRC.

Oxaliplatin has been proven for its specificity against colorectal tumors, thereby becoming a standard therapeutic in the management of this malignancy (5). However, its clinical application is restricted due to drug resistance and toxic side effects (6). Although research has been conducted through laboratory‑based and clinical studies to improve and optimize therapeutic potency, high efficiency and safe treatment options remain the focus of ongoing studies. In recent years, chemo‑therapeutic drugs and gene‑based combination therapy have become one of the most promising and active research fields in medicine (7).

Oxaliplatin functions predominantly via the formation of drug‑DNA adducts that block DNA synthesis, thereby triggering a cellular response and eventually leading to cell apoptosis (8). Translesion DNA synthesis (TLS) is a strategy for tolerating DNA damage, which serves an essential role in the maintenance of genome stability (9). Recent studies have revealed that TLS polymerase contributes to the development of platinum resistance in cancer cells (10), particularly polymerase ζ (11). REV3, the catalytic subunit of polymerase ζ, has attracted increased attention from researchers and a series of related reports can be found (12‑15), while another subunit, mitotic arrest deficient 2 like 2 (MAD2L2; also known as REV7), has been rarely studied (11). The ubiquitin (Ub) proteasome pathway (UPP) is the most important pathway involved in intracellular protein degradation.
degradation (16). The 26S proteasome is an essential multi-catalytic protease complex, which serves key roles in the function of the UPP. The 26S proteasome consists of proteasome 26S subunit, non-ATPase 13 (PSMD13) and a few additional components, such as proteasomal Ub receptor, proteasome 26S subunit, ATPase 1, Ub specific peptidase 14 and Ub C-terminal hydrolases 37 (17,18). Specific proteins involved in DNA damage repair, cell cycle regulation and apoptosis are the targets of the UPP (19). However, the underlying regulatory mechanism between the expression level of MAD2L2 and the UPP has not yet been elucidated. The current study proposed that the UPP may be involved in DNA damage repair of tumor cells caused by TLS and oxaliplatin, which may be mediated by regulating the expression levels of MAD2L2, thereby affecting cell apoptosis. MG132, a specific inhibitor of the 26S proteasome, was selected as an appropriate experimental compound to be used in the present study.

The present study aimed to investigate the antitumor effect and possible mechanism of MAD2L2, in order to provide a rationale for the clinical treatment of colon cancer.

Materials and methods

Cell culture and treatment. Colon cancer cell lines, HCT116 and SW620, were obtained from the American Type Culture Collection. Cells were incubated in DMEM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) and Penicillin-Streptomycin Solution (10,000 U/ml; Beyotime Institute of Biotechnology) at 37˚C and 5% CO₂.

Gene expression was knocked down using small interfering (si)RNA. Cells were transfected with 10 µM MAD2L2 siRNA and negative control siRNA using Lipofectamine™ RNAi MAX (Invitrogen; Thermo Fisher Scientific, Inc.) at 37˚C for 48 h. siRNA were designed and synthesized by Shanghai GenePharma Co., Ltd. The siRNA sequences were as follows: MAD2L2 forward, 5'-AAAAGAGCGACGUUAC GUGGAATT-3' and reverse, 5'-UUCCAGGUAACGUG CAUCUUTT-3'; and negative control forward, 5'-UUUCCGC GAACGUGACCTTT-3' and reverse, 5'-ACGUGGAC GGGGGAAG-3'. Reverse transcription-quantitative PCR (RT-qPCR) and western blotting were performed to identify transfection efficiency after 48-h transfection.

Cells were treated with oxaliplatin (Jiangsu Hengrui Medicine Co., Ltd.) and MG132 (MedChemExpress) at 37˚C for 24 h. The concentrations of both drugs under the current experimental condition were recalculation according to previous studies: Oxaliplatin, 50 µM in HCT116 cells and 90 µM in SW620 cells; and MG132, 18 µM in HCT116 cells and 36 µM in SW620 cells. As a control, the blank group received the same volume of 1% dimethyl sulfoxide (DMSO) vehicle as the other groups.

RT-qPCR. RT-qPCR was performed to detect and quantify mRNA. Total RNA was extracted from experimental cells using TRIzol® reagent (Beyotime Institute of Biotechnology). cDNA was produced using SYBR Premix Ex TaqII (TliRNaseH Plus; Takara Biotechnology Co., Ltd.) from the extracted RNA. RT reactions were conducted under the following conditions: 37˚C for 15 min, 85˚C 5 sec, maintained at 4˚C. qPCR amplification reactions were carried out in the Applied Biosystems™ 7500 Fast Real Time PCR system using a PowerUp™ SYBR™ Green Master Mix (both Thermo Fisher Scientific, Inc.). Available primers were obtained from Sangon Biotech, Co., Ltd., and the sequences of primers are as follows: MAD2L2 forward, 5'-CCAGGCTGTACCTTACA GTC-3' and reverse, 5'-TCTTCCAGTAAAGCTGATC-3' and GAPDH forward, 5'-ACCACTTCCACCTTGTGAC-3' and reverse, 5'-CACCACCCGTGGTCTAGG-3'. The thermocycling conditions were as follows: Initial denaturation at 95˚C for 2 min; followed by 40 cycles of denaturation at 95˚C for 3 sec and annealing/elongation at 60˚C for 30 sec; followed by a final extension step at 60˚C for 1 min. Finally, the relative gene expression values were calculated using the 2^−∆∆Cq method (20).

Western blotting. Western blotting was performed to separate and identify proteins. Total proteins were extracted using RIPA buffer (Beyotime Institute of Biotechnology), followed by the determination of the protein concentration using a BCA kit (Nanjing KeyGen Biotech. Co., Ltd.). Proteins (20-30 µg/well) were separated via 12% SDS-PAGE at 120 V and then transferred into 0.2-µm PVDF membrane under wet conditions at 300 mA. The blotted membranes were blocked with 5% non-fat milk for 2 h at room temperature. Antibodies were diluted in TBS-Tween-20 (1% TBS and 0.1% Tween). Primary antibodies were incubated at 4˚C overnight and secondary antibodies were incubated at room temperature for 1 h. Chemiluminescent signals were detected using Pierce™ ECL Western Blotting substrate (cat. no. 32109; Thermo Fisher Scientific, Inc.). Images were captured using Bio-Rad ChemiDOC XRS® system (Bio-Rad Laboratories, Inc.) and analyzed by Image Lab Software (version 5.2.1; Bio-Rad Laboratories, Inc.). The following antibodies were used: Primary antibodies, MAD2L2 (cat. no. sc135977; 1:500; Santa Cruz Biotechnology, Inc.), PSMD13 (cat. no. ab229812; 1:1,000; Abcam), Bax (cat. no. bs-0127R; 1:200; BIOSS), Bak (cat. no. bs-1284R; 1:200; BIOSS), Bcl-2 (cat. no. bs-0032R; 1:200; BIOSS) and GAPDH (cat. no. AB-P-R 001; 1:1,000; Hangzhou Goodhere Biotechnology Co., Ltd.); Secondary antibodies, goat Anti-Rabbit IgG H&L (HRP) (cat. no. ab6721; 1:10,000; Abcam) and goat Anti-Mouse IgG H&L (HRP) (cat. no. ab205719; 1:10,000; Abcam).

MTT assay. Cell viability was investigated using an MTT assay kit (Nanjing KeyGen Biotech Co., Ltd.). The cell count was adjusted to 1x10⁴ cells/ml. Cells were treated with oxaliplatin and MG132 in 96-well plate at 37˚C for 24 h. MTT solution was added and incubated for 30 min at 37˚C until the solution turned purple. DMSO was used for dissolving the purple crystals. Absorbance was measured using Multiskan™ GO microplate spectrophotometer (Thermo Fisher Scientific, Inc.) at 570 nm. The percentage of cell viability was calculated.

Flow cytometry. Cell apoptosis was detected via flow cytometry (BD Accuri™ C6; BD Biosciences). EDTA-free trypsin (Hyclone Laboratories, Inc.) was used to detach the experimental cells. According to the instructions of the Annexin V-FITC/PI kit (BD Biosciences), each group of cells was incubated with 5 µl Annexin V-FITC for 15 min at 2-8˚C.
Subsequently, 10 µl PI was added and incubated for 5 min at 2-8°C. Cells were analyzed within 30 min after staining using BD Accuri C6 software (version 5.0; BD Biosciences). The apoptotic rate was calculated as the percentage of early and late apoptotic cells.

**TUNEL assay.** DNA fragmentation, which is a marker of cell apoptosis (2), was detected using the TUNEL BrightGreen Apoptosis Detection kit (cat. no. A112-02; Vazyme Biotech Co., Ltd.). The cells were cultured on microscope slides, fixed with 4% formaldehyde at room temperature for 15 min and permeabilized with 0.25% Triton® X-100 at room temperature for 20 min. TUNEL staining was performed according to the manufacturer's instructions; cells were stained with 50 µl Recombinant TdT Enzyme at 37°C for 60 min and with 50 µl BrightGreen Labeling Mix at 37°C for 60 min. The slides were then immersed into 2 µg/ml DAPI solution and stained in the dark for 5 min. The samples were examined via fluorescence microscopy (DFC450 C; Leica Microsystems, Inc.); 10 visual fields were randomly selected per slide at x400 magnification.

**ELISA.** Total cell protein was extracted using RIPA buffer (Beyotime Institute of Biotechnology) from experimental cells. The activity of PSMD13 was detected using an ELISA kit (cat. no. ml-55255; Enzyme-linked Biotechnology Co., Ltd.). According to the manufacturer's instructions, standard wells, testing sample wells and blank wells were set. Standard and blank proteins were obtained from the ELISA kit. Standard protein was diluted to a range of 0, 50, 100, 150, 200, 250 and 300 ng/ml. Each concentration of these standard samples was added to standard wells, 50 µl/well; extracted protein samples were added to the testing well, 50 µl/well; And 50 µl blank protein was added to the blank well. Subsequently, 80 µl HRP-conjugated antibody was immediately added to the
well and incubated at 37°C for 1 h. Chromogenic substrate A (50 µl) and chromogenic substrate B (50 µl) were added and incubated at 37°C for 10 min, in the dark. Finally, 50 µl stop solution were added to each well to terminate the reaction. The optical density was measured at 450 nm. A standard curve was constructed and the corresponding concentration of PSMD13 was calculated.

Statistical analysis. SPSS 21.0 (IBM Corp.) was used for statistical analysis and GraphPad Prism 5 (GraphPad Software, Inc.) was used to generate the figures and mark the statistical difference. Data are presented as the mean ± SD. An unpaired Student’s t-test was used for comparison between two independent samples. One-way ANOVA was used for comparisons between groups, followed by Tukey's multiple comparisons test as the post-hoc test. P<0.05 was considered to indicate a statistically significant difference. All experiments were repeated ≥3 times.

Results

MAD2L2 expression regulated by oxaliplatin and MG132 in human colon cancer cells. Cells were treated with oxaliplatin and MG132. The MTT data indicated that cells treated with oxaliplatin or MG132 had a significant decrease in their viability compared with the blank group, but a synergistic effect was not observed during the co-treatment of oxaliplatin and MG132 (Table I). The western blotting results demonstrated that oxaliplatin and MG132 caused a significant decrease in the protein expression level of MAD2L2, but a synergistic effect was not observed in the co-treatment group (Fig. 1). These results indicated that the expression level of MAD2L2 was decreased by oxaliplatin and MG132 in human colon cancer cells, but no synergistic effects were observed.

Knockdown of MAD2L2 promotes Bcl-2-mediated apoptosis of colon cancer cells. Since oxaliplatin and MG132 were identified to affect the expression level of MAD2L2, the associations between them were investigated. Cells were transfected with siMAD2L2; compared with the negative control group, the mRNA expression levels of MAD2L2 were significantly downregulated in the siMAD2L2 group (Fig. 2). Subsequently, the experimental cells were treated with oxaliplatin and MG132. The MTT data revealed that, compared with the negative control group, siMAD2L2 caused a significant decrease in cell viability (Table II). Compared with the siMAD2L2 group, cell viability was suppressed by the co-treatment of siMAD2L2 and oxaliplatin, whereas it was increased by the co-treatment of siMAD2L2 and MG132. A synergistic effect was not observed during triple co-treatment with siMAD2L2, oxaliplatin and MG132 (Table II).
As shown by western blotting, compared with negative control group, siMAD2L2 significantly increased the expression levels of the pro-apoptotic proteins Bax and Bak, as well as decreased the expression level of the anti-apoptotic protein Bcl-2 (Fig. 3). Compared with siMAD2L2 group, cells co-treated with siMAD2L2 and oxaliplatin had increased Bax and Bak expression, and increased Bcl-2 expression. Compared with siMAD2L2 and oxaliplatin co-treatment group, the expression levels of Bax and Bak were significantly decreased after co-treatment with siMAD2L2, oxaliplatin and MG132, while Bcl-2 expression was higher (Fig. 3). This apoptotic effect was further confirmed by the flow cytometry and TUNEL assay results (Figs. 4 and 5). These observations suggested that the Bcl-2 pathway may be involved in the cell apoptosis mediated by MAD2L2.

siMAD2L2-induced suppression of PSMD13 is regulated by oxaliplatin and MG132. Previous studies reported that DNA damage-induced cytotoxic effects were inhibited by MG132 (21-23). Therefore, the activity of PSMD13, a key

Figure 3. Knockdown of MAD2L2 expression promotes Bcl-2-mediated apoptosis of colon cancer cells. The cells were treated with negative siRNA, siMAD2L2, siMAD2L2 + oxaliplatin, siMAD2L2 + MG132 and siMAD2L2 + oxaliplatin + MG132 (oxaliplatin was incubated for 24 h at 50 and 90 µM with HCT116 and SW620 cells, respectively; MG132 was incubated for 24 h at 18 and 36 µM with HCT116 and SW620 cells, respectively). Western blotting was performed to detect the expression levels of cell apoptosis-associated proteins. (A) Expression levels of Bax, Bak and Bcl-2 proteins in HCT116 and SW620 cells. One-way ANOVA followed by Tukey’s multiple comparisons test was used to determine the statistical significance in (B) HCT116 and (C) SW620 cells. The data are presented as the mean ± SD. n=3. *P<0.05 vs. negative group; $P<0.05 vs. siMAD2L2 group; &P<0.05 vs. siMAD2L2 + oxaliplatin group; #P<0.05 vs. siMAD2L2 + MG132 group. MAD2L2, mitotic arrest deficient 2 like 2; si, small interfering RNA.
protein of the UPP, was evaluated via ELISA. The results demonstrated that, compared with the negative control group, the activity and expression level of PSMD13 protein were significantly increased in the siMAD2L2 group. Compared with the siMAD2L2 group, PSMD13 activity was mitigated by the co‑treatment of siMAD2L2 and MG132, whereas it was promoted by the co‑treatment of siMAD2L2 and oxaliplatin. A synergistic effect was not observed during triple co‑treatment with siMAD2L2, oxaliplatin, and MG132, siMAD2L2 + oxaliplatin + MG132 (oxaliplatin was administered for 24 h at 50 and 90 µM to HCT116 and SW620 cells, respectively; MG132 was administered for 24 h at 18 and 36 µM to HCT116 and SW620 cells, respectively). The activity of PSMD13 was determined using an ELISA. PSMD13, proteasome 26S subunit, non-ATPase 13.

### Table III. Activity of PSMD13 in human colorectal cancer cells.

| Treatment                          | HCT116       | SW620       |
|------------------------------------|--------------|-------------|
| Negative                           | 293.21±31.25 | 280.31±6.93 |
| siMAD2L2                           | 385.68±37.13 | 370.62±22.43 |
| siMAD2L2 and oxaliplatin           | 485.07±44.17 | 459.15±28.11 |
| siMAD2L2 and MG132                 | 359.72±36.52 | 334.73±3.71  |
| siMAD2L2, oxaliplatin and MG132    | 418.46±33  | 411.28±2.67  |

*a* P<0.05 vs. negative group; *b* P<0.05 vs. siMAD2L2 group; *c* P<0.05 vs. siMAD2L2 + oxaliplatin group; *d* P<0.05 vs. siMAD2L2 + MG132 group. One-way ANOVA followed by Tukey’s multiple comparisons test was used to determine statistical significance. The data are presented as the mean ± SD. n=3. The cells were treated with negative siRNA, siMAD2L2, siMAD2L2 + oxaliplatin, siMAD2L2 + MG132, siMAD2L2 + oxaliplatin + MG132 (oxaliplatin was administered for 24 h at 50 and 90 µM to HCT116 and SW620 cells, respectively; MG132 was administered for 24 h at 18 and 36 µM to HCT116 and SW620 cells, respectively). The activity of PSMD13 was determined using an ELISA. PSMD13, proteasome 26S subunit, non-ATPase 13.

Discussion

MAD2L2, also called REV7 or MAD2B, encodes a core subunit of DNA polymerase ζ (24). Previous studies have reported that, in addition to maintaining genomic stability, MAD2L2 was also involved in multiple cellular functions, such as drug resistance reversal, epithelial stromal transformation transcription and signal transduction events (25‑27). In the present study, the aim was to investigate the effects of MAD2L2-induced cell apoptosis.

Previous studies have shown that DNA polymerase ζ plays an important role in the regulation of platinum resistance and REV3 has been considered the main focus (28); however, the role of MAD2L2 has been underestimated. In the present study, MAD2L2 was selected as the target gene; the results revealed that MAD2L2 promoted oxaliplatin-induced apoptosis. In the present study, human colon cancer cells, HCT116 and SW620, were selected. Cells were characterized for DNA damage by oxaliplatin. The protein expression level of MAD2L2 was found to be significantly downregulated. Flow cytometry and TUNEL results demonstrated that treatment with siMAD2L2 or oxaliplatin alone increased the apoptosis of both HCT116 and SW620 cells, whereas cells co‑treated with siMAD2L2 and oxaliplatin significantly promoted apoptosis. The results of western blotting showed that knockdown of MAD2L2 expression caused by RNA interference or oxaliplatin increased the expression levels of pro-apoptotic proteins Bax and Bak and decreased the expression levels of anti-apoptotic protein Bcl-2, compared with the negative control group. These results

![Figure 4. siMAD2L2-induced cell apoptosis is regulated by oxaliplatin and MG132 in HCT116 and SW620 cells. The cells were treated with oxaliplatin or MG132 alone, or co‑treated with oxaliplatin and MG132 for 24 h (oxaliplatin was incubated at 50 and 90 µM to HCT116 and SW620 cells, respectively; MG132 was incubated at 18 and 36 µM to HCT116 and SW620 cells, respectively). The induction of cell apoptosis was determined via flow cytometry.](image)
indicated that oxaliplatin promoted siMAD2L2-induced apoptosis of colon cancer cells, and this process was associated with the Bcl-2 family mediated cell apoptosis pathway.

In order to investigate the causes of MAD2L2-induced cell apoptosis, the present study focused on the UPP, which is responsible for the majority of intracellular protein degradation (29). This system exerts its biological effect via the cooperation of E1/E2/E3. Ub is activated by E1 and is then transferred to E2, which permits it to be sequentially conjugated to E3. E3 recognizes target substrates and catalyzes the covalent attachment of Ub to it (30). Finally, the substrates modified with polyubiquitin chains are delivered to the 26S proteasome for proteolytic destruction. Here, PSMD13 serves an important role (31).

In the present study, the activity of PSMD13 was evaluated via ELISA and further confirmed by western blotting. The results showed that the activity and protein expression level of PSMD13 were significantly increased by siMAD2L2. In addition, MG132, the inhibitor of proteasome, decreased the expression of MAD2L2, while reducing the siMAD2L2-induced cell apoptosis. These results suggest that the UPP was implicated in the regulation of TLS.

TLS depends on the orderly assembly of DNA polymerases (32). Cells are constantly exposed to DNA damage agents, such as UV, methyl methanesulfonate and other cytotoxic factors (33). Once DNA damage occurs, proliferating cell nuclear antigen (PCNA) can be recruited and mono-ubiquitinated...
by Rad18-Rad6 at Lys164 (K164), and Ub-PCNA mediates cellular response by TLS polymerases (34,35). MAD2L2 helps to coordinate the nucleotide insertion and extension steps of lesion bypass (36). Interestingly, Rad18 and Rad6 are particularly important E2 and E3 enzymes, which function as Ub conjugating and Ub ligase enzymes, respectively, and have been shown to be involved in the UPP, which mediates the degradation of proteins (37).

In the present study, the protein expression level of MAD2L2 was inhibited when the cells were treated with MG132. In addition, cell apoptosis was reduced by MG132 compared with the co-treatment of siMAD2L2 and oxaliplatin. Based on these results, it was suggested that the UPP may be one of the responders of TLS-related DNA damage in colon cancer cells. DNA lesions that are induced by oxaliplatin or siMAD2L2 may promote the cooperation between Rad6 and Rad18, which then activate PSMD13, finally resulting in the degradation of MAD2L2 protein. Such agents arrest TLS, trigger the accumulation of DNA damage and promote cancer cell apoptosis (38).

Although the present study indicated that both oxaliplatin and MG132 exerted impacts on siMAD2L2-induced cell apoptosis, these factors were not simply synergistic or antagonistic. More direct evidence is needed for effective treatment of colon cancer in the future. In conclusion, the present study demonstrated oxaliplatin promoted siMAD2L2-induced colon cell apoptosis, which was regulated by the UPP. Overall, the present study provides a theoretical basis for improving the clinical efficacy of colon cancer by combining chemotherapy and gene therapy.

Acknowledgements
I would like to extend my sincere gratitude to Professor Hao Wang (School of Pharmacy, Minzu University of China), Professor Jianmin Sun (School of Basic Medical Sciences, Ningxia Medical University) for their intellectual guidance, valuable comments and enlightening suggestions for my study and manuscript preparation.

Funding
The present study was supported by the National Natural Science Foundation of China (grant no. 31360251) and West China first-class Disciplines Basic Medical Sciences at Ningxia Medical University (grant no. NXYLXK2017B07).

Availability of data and materials
The datasets used during the current study are available from the corresponding author on reasonable request.

Authors' contributions
LM and FX designed the study. YL performed cell culture, transfection experiments and drug sensitivity tests. HTS contributed to the ELISA and western blotting assays. XPZ and XL performed the flow cytometry and TUNEL assays. LM and HTS acquired and interpreted the data. FFK and YS assisted...
The authors declare that they have no competing interests.

Competing interests

The authors declare that they have no competing interests.

References

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin 70: 7-30, 2020.
2. Crowley LC, Marfell BJ and Waterhouse MJ: Detection of DNA fragmentation in apoptotic cells by TUNEL. Cold Spring Harb Protoc: 2016, 2016.
3. Zhou J, Zheng R, Zhang S, Zeng H, Wang S, Chen R, Sun K, Li M, Gu J, Zhuang G and Wei W: Colorectal cancer burden and trends: Comparison between China and major burden countries in the world. Chin J Cancer Res 33: 1-10, 2021.
4. National Health Commission Of The People's Republic Of China: National guidelines for diagnosis and treatment of colorectal cancer 2020 in China (English version). Chin J Cancer Res 32: 415-445, 2020.
5. Sharma G, Anghore D, Khare R and Rawal RK: Oxalaplatin for colorectal cancer therapy: A review. Clin Cancer Drugs 5: 13-27, 2018.
6. Brown A, Kumar S and Thounpouw PB: Cisplatin-based chemotherapy of human cancers. J Cancer Sci Ther 11: 97, 2019.
7. McQuade RM, Stoianovska V, Bornstein JC and Nurgali K: PtDNA polymerase zeta in human cells. Proc Natl Acad Sci USA 115: E8191-E8200, 2018.
8. Feng L, Wei W, Heng Z, Yantao H and Chunbo W: Knockdown of REV7 inhibits breast cancer cell migration and invasion. Oncol Res 24: 315-325, 2016.
9. Rosenberg SC and Corbett KD: The multifaceted roles of the HORMA domain in cellular signalling. J Cell Biol 211: 745-755, 2015.
10. Hara K, Taharazako S, Ikeda M, Fujita H, Mikami Y, Kikuchi S, Hishiki A, Yokoyama H, Ishikawa K, Kanno S, et al: Dynamic feature of mitotic arrest deficient 2-like protein 2 (MAD2L2) and structural basis for its interaction with chromosome alignment maintainment phosphorylating (CAMP). J Biol Chem 292: 17658-17667, 2017.
11. Sanders MA, Haynes B, Nangia-Makker P, Polin LA and Shekhar MP: Pharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs. J Biol Chemistry 292:10347-10363, 2017.
12. Rizzo AA and Korzhnev DM: The Rev1-Pol, translesion synthesis mutasome: Structure, interactions and inhibition. Enzymes 45: 139-181, 2019.
13. Fernandes E, Fonseca TG, Carriço T, Mestre N, Tavares Á and Bebianno MF: Cytotoxic responses of the anticancer drug cyclophosphamide in the mussel Mytilus galloprovincialis and comparative sensitivity with human cells lines. Chemosphere 261: 127678, 2020.
14. Kanao R and Masutani C: Spatiotemporal regulation of PCNA ubiquitination in damage tolerance pathways. J Cell Sci 129: 3159-3169, 2016.
15. Rizzo AA, Vassel FM, Chatterjee N, D’Souza S, Li Y, Hao B, Hemann MT, Walker GC and Korzhnev DM: Rev7 dimerization is important for assembly and function of the Rev1/Pol translesion synthesis complex. Proc Natl Acad Sci USA 115: E8191-E8200, 2018.
16. Watson MT and Gildenberg MS: Structure of DNA polymerase ζ: Capturing the getaway driver. Nat Struct Mol Biol 27: 1-2, 2020.
17. Suzuki T, Sassa A, Gru P, Gupta RC, Johnson F, Adachi N and Nohmi T: Error-prone bypass patch by a low-fidelity variant of DNA polymerase ζ in human cells. DNA Repair (Amst) 100: 103052, 2021.
18. Gaczynska M and Osmulski PA: Targeting protein-protein interactions in the ubiquitin-proteasome pathway. Adv Protein Chem Struct Biol 110: 123-165, 2018.
19. Bi W, Zhu L, Zeng Z, Jing X, Liang Y, Guo L, Shi Q, Xu A and Tao E: Investigations into the role of 26S proteasome non-ATPase regulatory subunit 13 in neuroinflammation. Neuroimmunomodulation 21: 331-337, 2014.